Know Cancer

forgot password

A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation

Phase 2
21 Years
Not Enrolling
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)

Thank you

Trial Information

A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation

The proposed study will evaluate a regimen using treosulfan, fludarabine and low-dose TBI in
children and adolescents with AML or MDS undergoing allogeneic HCT. We expect this regimen
to yield lower toxicity and at least equivalent rates of disease control and overall
survival, compared to current standard myeloablative regimens. The primary objective of
this study is to determine the safety and preliminary efficacy of a transplant preparative
regimen consisting of treosulfan, fludarabine and low-dose TBI for children with AML and
MDS. The primary endpoint will be overall survival (OS) at one year. Secondary objectives
to be studied include: pharmacokinetic (PK) profile of treosulfan in children < 40 kg,
non-relapse mortality, disease-free survival, incidences of neutrophil and platelet
engraftment, donor chimerism, acute and chronic graft-versus-host disease (GVHD), and

Inclusion Criteria:

1. Age < 21 years.

2. Disease and disease status:

- Acute myeloid leukemia (AML) in morphologic remission (defined as < 5% blasts in
a bone marrow aspirate of adequate cellularity performed within 28 days from
start of conditioning).

- Myelodysplastic syndrome (MDS): Any 2001 WHO classification subtype (Appendix
I). RAEB-2 patients may proceed directly to transplant, but may also be
considered for induction chemotherapy before transplant. Patients with ≥20%
morphologic marrow blasts will require induction therapy to reduce morphologic
marrow blasts below 5% before transplant.

3. Karnofsky Index or Lansky Play-Performance Scale > 70 % on pre-transplant evaluation.
Karnofsky scores must be used for patients > 16 years of age and Lansky scores for
patients < 16 years of age.

4. Able to give informed consent if > 18 years, or with a legal guardian capable of
giving informed consent if < 18 years.

5. Negative pregnancy test (serum or urine β-HCG) for females of childbearing potential.

6. A single previous autologous or allogeneic HCT is allowed as long as the time from
first to second transplant hematopoietic cell infusion is no less than 6 months.

7. With a suitable allogeneic hematopoietic cell donor including, as available:

- HLA-identical related donor matched for HLA-A, -B, and -C at the serologic level
at minimum and -DRB1 at high resolution by molecular typing. A single locus
mismatched related donor (7/8 matched) is permitted only if there are no 8/8
matched unrelated donors available.

- Unrelated volunteer donor matched for HLA-A, -B, -C and -DRB1 defined by high
resolution molecular typing. A single HLA antigen or allele mismatch (7/8
matched) is permitted.

- Unrelated cord blood (UCB) matched to the recipient at a minimum of 4 of 6 loci
at HLA-A, and -B by intermediate resolution and -DRB1 by high resolution. Cord
blood unit(s) will be selected using the following criteria:

1. Unit selection is based on the cryopreserved total nucleated cell (TNC)
dose and matching at HLA-A, -B intermediate resolution and -DRB1 high
resolution typing. While HLA-C antigen/allele level typing is not
considered in the matching criteria, if available, it may be used to
optimize unit selection.

2. Selection of two UCB units is required if a single UCB unit will not
provide a sufficient cell dose (see Table 1 below). When two UCB units are
not required per Table 1, two UCB units may be used with approval of the
study chair or designee. When two units are selected, the following rules

- The UCB unit with the least HLA disparity with the patient, followed by the
larger cell dose for equivalently matched units, will be considered unit #1
(selection priority is 6/6 match >5/6 match>4/6 match).

- An additional UCB unit may be required to achieve the required cell dose, as
outlined in the table below. The second unit will be the one that most closely
HLA matches the patient and meets minimum size criteria as outlined below (i.e.
a smaller and more closely matched unit will be selected over a larger less well
matched unit as long as minimum cell dose criteria are met).

- Each UCB unit MUST contain at least 1.5 x 10^7 TNC per kilogram recipient

3) Other comments about cord blood unit selection:

- Use of unlicensed cord blood units will adhere to current federal regulatory
requirements for procurement.

- Units will be selected based on the TNC dose and HLA matching.

- A UCB unit that is 4/6 or 5/6 mismatched but homozygous at the locus of mismatch
should be chosen over a 5/6 unit with bidirectional mismatch even if the latter
unit provides a larger cell dose. This is only applicable to choosing units
within a given match grade.

- Within the best HLA match grade, the unit containing the greatest number of
cells will be chosen. If there are two units of equivalent cell dose within a
match level, choose the unit with best match by higher resolution molecular
typing, if known.

- Other factors to be considered:

i. Within the same HLA match grade, matching at both DR loci is preferable. ii.
UCB units sourced from cord blood banks located in the United States are

iii. Younger units are preferred over older units, all other factors being equal.

8. Adequate organ function, defined as:

- Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 50% of predicted by
pulmonary function tests (PFTs). For children who are unable to perform for PFTs
due to age, the criteria are: no evidence of dyspnea at rest and there is no
need for supplemental oxygen.

- Renal: GFR estimated by the updated Schwartz formula ≥ 90/min/1.73 m2, i.e.
height (cm)/serum creatinine (mg/dl) > 220. If the estimated creatinine
clearance is < 90 ml/min/1.73 m2, then renal function must be measured by
24-hour creatinine clearance or nuclear GFR, and must be > 70 mL/minute/1.73 m2

- Cardiac:

- Shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA) or
ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA)

- Hepatic:

- SGOT (AST) or SGPT (ALT) < 5 x upper limit of normal (ULN) for age.

- Conjugated bilirubin < 2.5 mg/dL, unless attributable to Gilbert's Syndrome.

9. Co- enrollment in PBMTC ONC 1001 (CIBMTR 09-MRD) protocol and/or CIBMTR 10-CBA
protocol (NMDP cord blood IND) is allowed. Co-enrollment on any other studies where
experimental therapy is being administered will be handled on a case-by-case basis
and must be discussed with the study chair or designee prior to enrollment.

Exclusion Criteria:

1. Pregnant or lactating females are ineligible as many of the medications used in this
protocol could be harmful to unborn children and infants.

2. Patients with HIV or uncontrolled fungal, bacterial or viral infections are excluded.
Patients with history of fungal disease during induction therapy may proceed if they
have a significant response to antifungal therapy with no or minimal evidence of
disease remaining by CT evaluation.

3. Patients with active CNS leukemia or any other active site of extramedullary disease
at the time of enrollment are not permitted. Note: Those with prior history of CNS or
extramedullary disease, but with no active disease at the time of pre-transplant
workup, are eligible.

4. Patients undergoing a course of chemotherapy using another investigational drug are
ineligible for study participation.

5. Patients diagnosed with Fanconi Anemia are ineligible for study participation.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary endpoint will be overall survival (OS) at one year

Outcome Description:

The primary objective of this study is to determine the safety and preliminary efficacy of a transplant preparative regimen consisting of treosulfan, fludarabine and low-dose TBI for children with AML and MDS. The primary endpoint will be overall survival (OS) at one year.

Outcome Time Frame:

1 year

Safety Issue:


Principal Investigator

Eneida Nemecek, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Doernbecher Children's Hospital, Oregon Health & Science University


United States: Food and Drug Administration

Study ID:




Start Date:

June 2013

Completion Date:

Related Keywords:

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • AML
  • MDS
  • Treosulfan
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Myelodysplastic Syndromes
  • Preleukemia



University of Michigan Ann Arbor, Michigan  48109-0624
Fred Hutchinson Cancer Research Center Seattle, Washington  98109
Children's Hospital of Philadelphia Philadelphia, Pennsylvania  19104
Medical University of South Carolina Charleston, South Carolina  29425-0721
Medical College of Wisconsin Milwaukee, Wisconsin  53226
Children's Hospital Los Angeles Los Angeles, California  90027-0700
Children's National Medical Center Washington, District of Columbia  20010-2970
Children's Mercy Hospital Kansas City, Missouri  64108
All Children's Hospital St. Petersburg, Florida  33701
Phoenix Children's Hospital Phoenix, Arizona  85016-7710
Methodist Children's Hospital of South Texas San Antonio, Texas  78229-3993
Nationwide Children's Hospital Columbus, Ohio  43205-2696
University of Minnesota Minneapolis, Minnesota  55455
City of Hope Duarte, California  91010
Cleveland Clinic Cleveland, Ohio  44195
Dana Farber Cancer Institute Boston, Massachusetts  02115
Johns Hopkins Baltimore, Maryland  21231
University of North Carolina, Chapel Hill Chapel Hill, North Carolina  27599
St. Jude's Children's Research Hospital Memphis, Tennessee  38105
Rady Children's Hospital San Diego, California  92123
University Hospitals Case Medical Center Cleveland, Ohio  44106
University of Wisconsin - Madison Madison, Wisconsin  53792
Children's Hospital of Colorado Aurora, Colorado  80045
Riley Hospital for Children/Indiana University Indianapolis, Indiana  46202
Children's Hospital of Alabama/UAB Birmingham, Alabama  35233
Kosair Children's Hospital - University of Louisville Louisville, Kentucky  40202
Children's Hospital/LSUHSC New Orleans New Orleans, Louisiana  70118
Washington University, St. Louis Children's St. Louis, Missouri  63130
OHSU/Doernbecher Children's Hospital Portland, Oregon  97239
Primary Children's Medical Center - University of Utah Salt Lake City, Utah  84111